Michael Bounds, MD
Vascular Surgery · Salisbury, MDNPI 1568755825
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,006 of the $6,266 with a category attached, or 63.9%. 38 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 38.7% of the total. Reporting peaked in 2024 at $1,860 and has fallen 61.3% since, to $719 in 2025.
Across 142 payments — averaging $44.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$2K
- Silk Road Medical, Inc.$1K
- Medtronic$847
- Johnson & Johnson$435
- Inari Medical, Inc.$211
- Bard Peripheral Vascular, Inc.$139
- plus $1K from 32 others
What the payments were for
- Travel & lodging$2,26036%
- Food & beverage$4,00664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 19 | $2,425 |
| Silk Road Medical, Inc. | 15 | $1,019 |
| Medtronic | 14 | $847 |
| Johnson & Johnson(2 entities) | 31 | $435 |
| Inari Medical, Inc. | 5 | $211 |
| Bard Peripheral Vascular, Inc. | 3 | $139 |
| Endologix LLC | 1 | $134 |
| Baxter Healthcare | 2 | $92 |
| Tactile Systems Technology Inc | 4 | $70 |
| Cardiovascular Systems Inc. | 3 | $60 |
| Organogenesis Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Angiodynamics, Inc. | 2 | $54 |
| Stryker | 2 | $47 |
| Smith+Nephew | 2 | $45 |
| Philips North America LLC | 3 | $44 |
| Solventum Corporation | 2 | $38 |
| Elutia, Inc. | 2 | $38 |
| Surmodics, Inc. | 2 | $37 |
| Shape Memory Medical Inc. | 1 | $35 |
| Bolton Medical Inc | 3 | $35 |
| Teleflex LLC | 2 | $34 |
| KCI USA, Inc. | 2 | $29 |
| Boston Scientific | 2 | $27 |
| Davol Inc. | 1 | $26 |
| Convatec Inc. | 1 | $25 |
| Integra Lifesciences Corporation | 1 | $24 |
| GSK | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Vertex | 1 | $20 |
| Abbott | 1 | $19 |
| Pfizer | 1 | $16 |
| Eagle Pharmaceuticals, Inc. | 1 | $16 |
| Cvrx, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Lemaitre Vascular, Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
| Bioventus LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$935
- GORE TAG Thoracic Endoprosthesis$870
- ENROUTE Transcarotid Neuroprotection System$725
- ENROUTE Transcarotid Stent System$725
- ENHANCE Transcarotid Peripheral Access Kit$725
- ENROUTE 0.014 Guidewire$725
- ENDURANT IIS$234
- FLOWTRIEVER CATHETER, S$163
- CT THROMBECTOMY SYSTEM KIT$163
- AFX2 Bifurcated Endograft System$134
How this compares
$6,266 in reported general payments places this provider in the 70th percentile of 104 vascular surgery providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 24 | $21,786 |
| EliquisApixaban | 16 | $19,240 |
| ClopidogrelClopidogrel Bisulfate | 143 | $2,159 |
| Atorvastatin Calcium | 54 | $644 |
| Oxycodone Hcl | 19 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $435 | $21,78624 claims |
| PfizerEliquis | $16 | $19,24016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 vascular surgery providers in Maryland.
Other vascular surgery in Salisbury
- Paul McNeillFrederick$302K
- John MartinAnnapolis$172K
- Caitlin HicksBaltimore$88K
- Shahab ToursavadkohiBaltimore$76K
- Michael OsgoodBel Air$57K
- Jeffrey WangGermantown$53K
- Frank CriadoBaltimore$52K
- Dustin YoonGermantown$36K
- Micah GirottiBel Air$35K
- Khanjan NagarshethBaltimore$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.